Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

Martina Burlando, Elena Campione, Aldo Cuccia, Giovanna Malara, Luigi Naldi, Francesca Prignano, Leonardo Zichichi

29-12-2022

https://doi.org/10.4081/dr.2023.9613

1790

PDF: 547

HTML: 77
A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata

Tueboon Sriphojanart, Saranya Khunkhet, Poonkiat Suchonwanit

30-11-2017

https://doi.org/10.4081/dr.2017.7399

4092

PDF: 908

HTML: 304
Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

13-09-2023

https://doi.org/10.4081/dr.2023.9839

2776

PDF: 993

HTML: 33
Treatment satisfaction among patients with psoriasis in Saudi Arabia

Mahdi Aldhafiri, Rahaf Almutairi, Reem Albejais, Asma Almubark, Hussain Alwesaibie, Mohammed Albesher, Manayer Almustihi

15-04-2024

https://doi.org/10.4081/dr.2024.9967

1081

PDF: 580

HTML: 35
Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Dimitris Rigopoulos, Aikaterini Patsatsi, Christina Antoniou, Dimitrios Sotiriadis, Angeliki Roussaki-Schulze, Nadia Boubouchairopoulou, Ioannis Skiadas, Vasillios Tsekouras, Ana Cristina Hernandez Daly

21-11-2022

https://doi.org/10.4081/dr.2022.9265

1554

PDF: 456

HTML: 29
Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines

Valeria Corazza, Francesco Cusano, Ornella De Pità, Luigi Rossi, G. Giovanni Virno

28-12-2021

https://doi.org/10.4081/dr.2022.9454

4128

PDF: 675

APPENDIX: 184

HTML: 17
Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

21-11-2022

https://doi.org/10.4081/dr.2022.9492

1740

PDF: 685

HTML: 88
Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease

Klaudia Miklusiak, Karol Miklusiak, Olga Kaczmarczyk, Dorota Cibor, Małgorzata Zwolińska-Wcisło

22-05-2023

https://doi.org/10.4081/dr.2023.9630

1085

PDF: 573

HTML: 82
Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

01-10-2018

https://doi.org/10.4081/dr.2018.7859

2033

PDF: 1074

HTML: 68
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

19-05-2023

https://doi.org/10.4081/dr.2023.9692

1074

PDF: 553

HTML: 24
Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

11-11-2024

https://doi.org/10.4081/dr.2024.10140

1020

PDF: 540

SUPPLEMENTARY MATERIAL: 165

HTML: 18
Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Fawaz Aljehani, Shumukh Alqahtani, Sara Alharbi, Seham Alsulami

06-12-2024

https://doi.org/10.4081/dr.2024.10171

1740

PDF: 463

HTML: 39
Refractory pityriasis rubra pilaris treated with abrocitinib

Filip Rob

09-01-2025

https://doi.org/10.4081/dr.2025.10105

441

PDF: 294

HTML: 16
Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Paolo Dapavo, Matteo Megna, Marina Talamonti

09-08-2024

https://doi.org/10.4081/dr.2024.9999

1781

PDF: 697

HTML: 99
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

17-03-2022

https://doi.org/10.4081/dr.2022.9282

1176

PDF: 834

HTML: 44
Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

30-07-2025

https://doi.org/10.4081/dr.2025.10379

459

PDF: 321

HTML: 3
Erythrodermic psoriasis improved by tildrakizumab

Giampaolo Trevisan, Lerica Germi, Luigi Naldi

23-11-2022

https://doi.org/10.4081/dr.2022.9448

1173

PDF: 625

HTML: 25
Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

Alexandra Maria Giovanna Brunasso, Sanja Javor, Emanuele Pontali, Simona Sola, Cesare Massone

29-07-2021

https://doi.org/10.4081/dr.2021.8797

3071

PDF: 654

HTML: 13
New and emerging therapies in cutaneous T-cell lymphoma

Gabriele Roccuzzo, Nicole Macagno, Silvia Giordano, Paolo Fava, Pietro Quaglino

02-10-2024

https://doi.org/10.4081/dr.2024.10002

1136

PDF: 625

HTML: 100
Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

Catharina Margrethe Lerche, Hans Christian Wulf

e13

14-09-2010

https://doi.org/10.4081/dr.2010.e13

2178

PDF: 865

HTML: 179
Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

14-03-2022

https://doi.org/10.4081/dr.2022.9091

2639

PDF: 641

HTML: 10
Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Marco May Lee, Vito Di Lernia, Francesca Peccerillo, Federico Bardazzi, Michela Tabanelli, Michela Ricci, Davide Melandri, Monica Corazza, Francesca Satolli, Andrea Conti

01-07-2025

https://doi.org/10.4081/dr.2025.10315

575

PDF: 291

HTML: 20
Certolizumab to treat hidradenitis suppurativa

Asem Shadid, Saud Alobaida, Yousef Binamer

27-10-2022

https://doi.org/10.4081/dr.2022.9566

1952

PDF: 739

HTML: 32
Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

30-05-2025

https://doi.org/10.4081/dr.2025.10414

755

PDF: 423

HTML: 30
Erythrodermic psoriasis treated with apremilast

John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

19-09-2016

https://doi.org/10.4081/dr.2016.6599

2148

PDF: 976

HTML: 603

1 - 25 of 46 items 1 2 > >>

Search

Search Results

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus

A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

Treatment satisfaction among patients with psoriasis in Saudi Arabia

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexible-dosing etanercept in patients with plaque psoriasis in Greece

Methotrexate in the therapeutic pathway of patients with psoriasis. Analysis of clinical practice data and comparison with guidelines

Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

Nightmares caused by isotretinoin in treating hidradenitis suppurativa: a case report and clinical insights

Refractory pityriasis rubra pilaris treated with abrocitinib

Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

Erythrodermic psoriasis improved by tildrakizumab

Mycobacterium kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: First report and literature review

New and emerging therapies in cutaneous T-cell lymphoma

Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy

Certolizumab to treat hidradenitis suppurativa

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

Erythrodermic psoriasis treated with apremilast

authors

reviewers

Categories

indexing

dermatopathology